ABOUT THE RESEARCHER

OVERVIEW

Dr. Daly's research is largely focused on novel, noninvasive techniques for the diagnosis and monitoring of cardiac allograft vasculopathy (CAV), including the development of serum biomarkers and novel imaging technologies.

Currently, he is studying the underpinnings of chronic allograft rejection—the major cause of mortality following pediatric heart transplant. Through his research, Dr. Daly aims to determine if endothelial injury and repair responses can be monitored in recipients of cardiac transplantation, and to establish if patterns of these biomarkers predict, or are associated with, the development of chronic allograft rejection. In addition, Dr. Daly's research aims to establish whether molecular imaging studies of myocardial blood flow and endothelial cell activation are associated with early CAV/chronic rejection.

BACKGROUND

Dr. Daly received his MD from Columbia University College of Physicians & Surgeons. He completed his internship and residency at the Children’s Hospital at Montefiore (Albert Einstein College of Medicine) and his fellowship at Boston Children's Hospital.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients. J Thorac Cardiovasc Surg. 2021 Feb 18. View abstract
  2. Retrospective Analysis of Clinical Genetic Testing in Pediatric Primary Dilated Cardiomyopathy: Testing Outcomes and the Effects of Variant Reclassification. J Am Heart Assoc. 2020 06 02; 9(11):e016195. View abstract
  3. The ABO-incompatible paradigm shifts only as far as allocation policy allows. J Heart Lung Transplant. 2020 07; 39(7):636-638. View abstract
  4. Brighter Future for Children with Congenital Heart Disease Requiring Heart Transplantation? A UNOS Registry Analysis over the Last Three Decades. J Heart Lung Transplant. 2020 Apr; 39(4S):S206-S207. View abstract
  5. Coagulation Monitoring Correlation with Bivalirudin Dosing in Pediatric Ventricular Assist Device Support. J Heart Lung Transplant. 2020 Apr; 39(4S):S467-S468. View abstract
  6. The TEAMMATE Trial: Study Design and Rationale of the First Pediatric Heart Transplant Randomized Clinical Trial. J Heart Lung Transplant. 2020 Apr; 39(4S):S207-S208. View abstract
  7. Marijuana in pediatric and adult congenital heart disease heart transplant listing: A survey of provider practices and attitudes. Pediatr Transplant. 2020 03; 24(2):e13640. View abstract
  8. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients. Transplantation. 2020 01; 104(1):e31-e37. View abstract
  9. Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients. Cardiol Young. 2020 Jan; 30(1):107-113. View abstract
  10. Current evaluation and management of plastic bronchitis in the pediatric population. Int J Pediatr Otorhinolaryngol. 2020 Mar; 130:109799. View abstract
  11. Myocardial Infarct After Marijuana Inhalation in a 16-year-old Adolescent Boy. Pediatr Dev Pathol. 2019 Jan-Feb; 22(1):80-86. View abstract
  12. Heart failure after the Norwood procedure: An analysis of the Single Ventricle Reconstruction Trial. J Heart Lung Transplant. 2018 07; 37(7):879-885. View abstract
  13. Managing risk of surgical procedures in pediatric transplant recipients taking mTOR inhibitors: What is the optimal strategy? Pediatr Transplant. 2018 02; 22(1). View abstract
  14. Clinical practice patterns are relatively uniform between pediatric heart transplant centers: A survey-based assessment. Pediatr Transplant. 2017 Aug; 21(5). View abstract
  15. The Evolution of a Pediatric Ventricular Assist Device Program: The Boston Children's Hospital Experience. Pediatr Cardiol. 2017 Jun; 38(5):1032-1041. View abstract
  16. Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation. J Heart Lung Transplant. 2018 04; 37(4):441-450. View abstract
  17. Into the hearts of babes: Stem cell therapy for pediatric heart failure. J Heart Lung Transplant. 2017 08; 36(8):830-832. View abstract
  18. Dilated Cardiomyopathy in a 2-Year-Old Infant. Clin Chem. 2017 01; 63(1):433-435. View abstract
  19. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. J Heart Lung Transplant. 2017 Apr; 36(4):434-442. View abstract
  20. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2016 11; 35(11):1295-1302. View abstract
  21. Is Endomyocardial Biopsy a Safe and Useful Procedure in Children with Suspected Cardiomyopathy? Pediatr Cardiol. 2016 Oct; 37(7):1200-10. View abstract
  22. Finding the correct role for heart transplant in the treatment of hypoplastic left heart syndrome. J Heart Lung Transplant. 2016 Mar; 35(3):299-300. View abstract
  23. What Is the Role of Developmental Disability in Patient Selection for Pediatric Solid Organ Transplantation? Am J Transplant. 2016 Mar; 16(3):767-72. View abstract
  24. Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation. 2015 Sep; 99(9):e132-9. View abstract
  25. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. Am J Transplant. 2016 Jan; 16(1):121-36. View abstract
  26. Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute. Cardiol Young. 2015 Aug; 25 Suppl 2:8-30. View abstract
  27. Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine. Cardiol Young. 2015 Aug; 25 Suppl 2:117-23. View abstract
  28. Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatr Nephrol. 2016 Jan; 31(1):41-51. View abstract
  29. Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection? Ann Transl Med. 2015 Mar; 3(4):47. View abstract
  30. Safety and efficacy of radiofrequency wire recanalization of chronic central venous occlusions. J Vasc Access. 2015 Jul-Aug; 16(4):309-14. View abstract
  31. Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. Pediatr Transplant. 2013 Nov; 17(7):661-9. View abstract
  32. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 2013 Oct 03; 168(3):2435-40. View abstract
  33. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013 Jan; 32(1):120-8. View abstract
  34. Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol. 2012; 3:54. View abstract
  35. Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience. J Heart Lung Transplant. 2012 Apr; 31(4):398-409. View abstract
  36. Sudden death after pediatric heart transplantation: analysis of data from the Pediatric Heart Transplant Study Group. J Heart Lung Transplant. 2011 Dec; 30(12):1395-402. View abstract
  37. Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT. Bone Marrow Transplant. 2011 Dec; 46(12):1532-9. View abstract
  38. Variant translocation with a deletion of derivative (9q) in a case of Philadelphia chromosome positive (Ph +) essential thrombocythemia (ET), a variant of chronic myelogenous leukemia (CML) with a poor prognosis. Leuk Lymphoma. 2005 Dec; 46(12):1801-6. View abstract